Insulet Corporation (PODD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Insulet Corporation stock (PODD) is currently trading at $216.00. Insulet Corporation PE ratio is 62.07. Insulet Corporation PS ratio (Price-to-Sales) is 5.61. Analyst consensus price target for PODD is $353.46. WallStSmart rates PODD as Hold.
- PODD PE ratio analysis and historical PE chart
- PODD PS ratio (Price-to-Sales) history and trend
- PODD intrinsic value — DCF, Graham Number, EPV models
- PODD stock price prediction 2025 2026 2027 2028 2029 2030
- PODD fair value vs current price
- PODD insider transactions and insider buying
- Is PODD undervalued or overvalued?
- Insulet Corporation financial analysis — revenue, earnings, cash flow
- PODD Piotroski F-Score and Altman Z-Score
- PODD analyst price target and Smart Rating
Insulet Corporation
📊 No data available
Try selecting a different time range
PODD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Insulet Corporation (PODD)
PODD trades 453% above its Graham fair value of $45.38, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Insulet Corporation (PODD) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, revenue growth, institutional own.. Concerns around price/book and eps growth. Fundamentals are solid but monitor weak areas for improvement.
Insulet Corporation (PODD) Key Strengths (4)
Revenue surging 31.20% year-over-year
103.03% of shares held by major funds and institutions
Large-cap company with substantial market presence
Solid profitability: $18 profit per $100 equity
Supporting Valuation Data
Insulet Corporation (PODD) Areas to Watch (6)
Very expensive at 10.6x book value
Earnings barely growing at 3.90%
Premium valuation at 5.6x annual revenue
Thin profit margins with limited profitability
Growth is fairly priced, not cheap, not expensive
Decent operational efficiency, solid but not exceptional
Supporting Valuation Data
Insulet Corporation (PODD) Detailed Analysis Report
Overall Assessment
This company scores 57/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 4 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Profitability is solid with Return on Equity at 18.10%. Growth metrics are encouraging with Revenue Growth at 31.20%.
The Bear Case
The primary concerns are Price/Book, EPS Growth, Price/Sales. Some valuation metrics including PEG Ratio (1.58), Price/Sales (5.61), Price/Book (10.55) suggest expensive pricing. Growth concerns include EPS Growth at 3.90%, which may limit upside. Profitability pressure is visible in Operating Margin at 18.70%, Profit Margin at 9.12%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 18.10% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 31.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Revenue Growth, Institutional Own.) and negatives (Price/Book, EPS Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PODD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PODD's Price-to-Sales ratio of 5.61x sits near its historical average of 6.02x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 12% below its historical high of 6.41x set in Mar 2026, and 0% above its historical low of 5.61x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~6.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Insulet Corporation (PODD) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Insulet Corporation is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 2.7B with 31% growth year-over-year. Profit margins are thin at 9.1%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 31% YoY, reaching 2.7B. This pace significantly outperforms most MEDICAL DEVICES peers.
Generating 48M in free cash flow and 183M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Insulet Corporation push profit margins above 15% as the business scales?
Growth sustainability: can Insulet Corporation maintain 31%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 62.1x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Insulet Corporation.
Bottom Line
Insulet Corporation is a high-conviction growth story with revenue accelerating at 31% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 9.1% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Insulet Corporation(PODD)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.